Clovis Oncology, Inc. released the presentation by Andrew D. Simmons, Ph.D., Clovis’ Senior Vice President,at the 3rd Targeted Radiopharmaceuticals Summit held virtually December 7-9, 2021. Dr. Simmons’ presentation, titled “Innovations in Peptide Targeted Radionuclide Therapies (PTRT) to Target Fibroblast Activation Protein (FAP) in Solid Tumors”, reviews the Company’s preclinical data and describes the Phase 1/2 study currently enrolling for its targeted radiotherapy candidate FAP-2286, the first PTRT and imaging agent targeting FAP to enter clinical development and the lead candidate in Clovis Oncology’s targeted radionuclide therapy (TRT) development program.
To
read more please visit:
Source: CLOVIS ONCOLOGY